Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibrx Biosciences (INBX) Change in Accured Expenses (2023 - 2025)

Inhibrx Biosciences (INBX) has disclosed Change in Accured Expenses for 3 consecutive years, with -$1.4 million as the latest value for Q4 2025.

  • Quarterly Change in Accured Expenses changed N/A to -$1.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$4.4 million through Dec 2025, down 112.15% year-over-year, with the annual reading at -$4.4 million for FY2025, 112.15% down from the prior year.
  • Change in Accured Expenses for Q4 2025 was -$1.4 million at Inhibrx Biosciences, up from -$1.5 million in the prior quarter.
  • The five-year high for Change in Accured Expenses was $21.8 million in Q2 2024, with the low at -$4.3 million in Q2 2025.
  • Average Change in Accured Expenses over 3 years is $6.1 million, with a median of $6.0 million recorded in 2024.
  • The sharpest move saw Change in Accured Expenses fell 5.05% in 2024, then tumbled 125.12% in 2025.
  • Over 3 years, Change in Accured Expenses stood at $17.4 million in 2023, then tumbled by 65.33% to $6.0 million in 2024, then crashed by 123.78% to -$1.4 million in 2025.
  • According to Business Quant data, Change in Accured Expenses over the past three periods came in at -$1.4 million, -$1.5 million, and -$4.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.